205 related articles for article (PubMed ID: 28413978)
1. Advances and Challenges in Drug Design of PPARδ Ligands.
Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM
Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978
[TBL] [Abstract][Full Text] [Related]
2. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
3. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
4. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
Miyachi H
Curr Med Chem; 2007; 14(22):2335-43. PubMed ID: 17896982
[TBL] [Abstract][Full Text] [Related]
6. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
8. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
[TBL] [Abstract][Full Text] [Related]
9. Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome.
Grewal AS; Beniwal M; Pandita D; Sekhon BS; Lather V
Med Chem; 2016; 12(1):3-21. PubMed ID: 26004782
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
[TBL] [Abstract][Full Text] [Related]
11. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
12. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
Savkur RS; Miller AR
Expert Opin Investig Drugs; 2006 Jul; 15(7):763-78. PubMed ID: 16787140
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.
Takahashi S; Tanaka T; Kodama T; Sakai J
Pharmacol Res; 2006 Jun; 53(6):501-7. PubMed ID: 16713711
[TBL] [Abstract][Full Text] [Related]
14. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
[TBL] [Abstract][Full Text] [Related]
15. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
16. Novel Cinnamic Acid Derivatives as Potential PPARδ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies.
Chauhan A; Grewal AS; Pandita D; Lather V
Curr Drug Discov Technol; 2020; 17(3):338-347. PubMed ID: 30868955
[TBL] [Abstract][Full Text] [Related]
17. PPAR delta agonists and metabolic diseases.
Kang K; Hatano B; Lee CH
Curr Atheroscler Rep; 2007 Jan; 9(1):72-7. PubMed ID: 17169250
[TBL] [Abstract][Full Text] [Related]
18. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
[TBL] [Abstract][Full Text] [Related]
19. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
